Market capitalization | $15.88m |
Enterprise Value | $29.19m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 14.89 |
P/S ratio (TTM) P/S ratio | 8.10 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -30.32% |
Revenue (TTM) Revenue | $1.96m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast OpGen, Inc.:
1 Analyst has issued a forecast OpGen, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 1.96 1.96 |
30%
30%
|
|
Gross Profit | 0.02 0.02 |
102%
102%
|
|
EBITDA | -8.07 -8.07 |
60%
60%
|
EBIT (Operating Income) EBIT | -8.75 -8.75 |
59%
59%
|
Net Profit | -22 -22 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OpGen, Inc. engages in the development of molecular information products and services for global healthcare settings. It offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
Head office | United States |
CEO | Hon Tan |
Founded | 2001 |
Website | www.opgen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.